HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

212.00p

By Sharecast

Date: Wednesday 31 Dec 2025

China NDA Acceptance-Savolitinib in Gastric Cancer	30-Dec-2025	ShareCast
Blocklisting Six Monthly Return	29-Dec-2025	ShareCast
NDA Acceptance in China for Fanregratinib	29-Dec-2025	ShareCast
Hutchmed launches development programme for next...	17-Dec-2025	ShareCast
Hutchmed medicines get renewed, new reimbursemen...	08-Dec-2025	ShareCast

HUTCHMED Licenses KRAS-EGFR-Antibody to GSK	03-Sep-2026	07:00	RNS
SANOVO trial demonstrated significant PFS benefit	01-Sep-2026	07:00	RNS
NMPA Approval for ATLED® (Fanregratinib) fo...	28-Aug-2026	07:00	RNS
Announcement pursuant to AIM Rule 17 Schedule 2(g)	18-Aug-2026	10:00	RNS
Orpathys+Tagrisso improved PFS & OS in EGFRm lung	17-Aug-2026	07:00	RNS

Chinese medicine firm employs Cambridge Universi...	23-Dec-2009	Guardian
Joint venture offers food for growth	09-Oct-2009	The Scotsman
Chi-Med unveils maiden profit	31-Jul-2009	The Scotsman
Chi-Med happy with drug tests	14-Jul-2009	The Scotsman
'Watershed' year depends on US drugs trial says ...	17-Mar-2009	The Scotsman

Questor: Hutchison China Meditech	03-Jul-2007	Telegraph
The Week Ahead: Wolseley investors seek calm ami...	19-Mar-2007	The Independent
The Investment Column: Hutchison China MediTech	21-Nov-2006	The Independent
Shares That Sound Good	02-Jun-2006	Motley Fool UK

No recent information was found.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.